Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

DIA analysis of EPS-urine from PCa and BPH patients

ABSTRACT: The objective of the experiment was to compare the proteome of EPS-urine from PCa and BPH patients.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Urine

DISEASE(S): Prostate Adenocarcinoma

SUBMITTER: Licia Elvira Prestagiacomo

LAB HEAD: Marco Gaspari

PROVIDER: PXD035942 | Pride | 2023-03-11

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Publications

Data-Independent Acquisition Mass Spectrometry of EPS-Urine Coupled to Machine Learning: A Predictive Model for Prostate Cancer.

Prestagiacomo Licia E LE Tradigo Giuseppe G Aracri Federica F Gabriele Caterina C Rota Maria Antonietta MA Alba Stefano S Cuda Giovanni G Damiano Rocco R Veltri Pierangelo P Gaspari Marco M

ACS omega 20230207 7

Prostate cancer (PCa) is annually the most frequently diagnosed cancer in the male population. To date, the diagnostic path for PCa detection includes the dosage of serum prostate-specific antigen (PSA) and the digital rectal exam (DRE). However, PSA-based screening has insufficient specificity and sensitivity; besides, it cannot discriminate between the aggressive and indolent types of PCa. For this reason, the improvement of new clinical approaches and the discovery of new biomarkers are neces ...[more]

PMID: 36844540

Similar Datasets

LC-MSMS analysis of human urine to identify early diagnostic biomarkers for prostate cancer

Project description:In order to detect proteins sensitive and specific enough to detect early stages of PCa, we performed a complex comparative proteomic study analyzing urine as a source for non-invasive biomarkers. We compared urine samples from patients with early PCa stages and Gleason score between 6 and 7 with samples from patients with BPH and other urological cancers, namely bladder and renal. The main goal of this study was to discover a diagnostic biomarker or set of biomarkers in urine, sufficiently sensitive to detect PCa in its early stages and specific enough to separate the disease from BPH or other urological cancers.

2018-01-02 | PXD008407 | Pride

Evaluation of microRNAs in urine samples as indicators of prostate cancer occurrence

2012-07-12 | GSE39314 | GEO

Evaluation of microRNAs in urine samples as indicators of prostate cancer occurrence

Project description:miRNAs have been proven to be very useful biomarkers, readily detectable in body fluids, particularly urine may be a valuable source to identify changes in miRNA levels that contribute to better differentiate prostate cancer (PCa) from benign prostate hyperplasia (BPH) cases. In order to characterize microRNA expression in urine samples from PCa, we analyzed expression of 376 microRNAs in 9 samples of PCa and 9 of BPH. The Normalized Ct values were compared between PCa and BPH. Statistical comparisons were made using Mann-Whitney U test, considering two different distributions. We found statiscally differences n expression for 21 miRNAs (Fold change >2 and P value<0.05). For the initial screening of all the studied samples, we selected only those with a concentration above 100 ng/ml, for a total of 9 samples of group of PCa and 9 BPH group. The isolated RNA was evaluated by measuring the absorbance at 260 nm and 280 nm. RNA aliquots from specimens were pooled and reverse transcription (RT) reaction was pweformed. In total, we formed 3 pools from BPH specimens and 3 from PCa ones. The RT product was used to perform a preamplification reaction. The product of preamplification teaction was loaded into the Taqman Homo sapiens microRNA Low density arrays (TLDA) panel A and amplification signal was detected using the 7900 FAST real time thermal cycler (ABI).

2012-07-12 | E-GEOD-39314 | biostudies-arrayexpress

Transcriptomic profiling of urine extracellular vesicles reveals alterations of CDH3 in prostate cancer

Project description:One of the challenges of current research in prostate cancer is to improve the differential non-invasive diagnosis of prostate cancer (PCa) and benign prostate hyperplasia (BPH). Extracellular vesicles (EV) are emerging structures with promising properties for intercellular communication. In addition, the characterization of EV in biofluids is an attractive source of non-invasive diagnostic, prognostic and predictive biomarkers. Here we show that urinary EV (uEV) from prostate cancer patients exhibit genuine and differential physical and biological properties. Importantly, transcriptomics characterization of uEVs led us to define the decreased abundance of Cadherin 3, type 1 (CDH3) transcript in uEV from PCa patients. Tissue and cell line analysis strongly suggested that the status of CDH3 in uEVs is a distal reflection of changes in the expression of this cadherin in the prostate tumor. Our results reveal that uEVs could represent a non-invasive tool to inform about the molecular alterations in prostate cancer. RNA extraction was performed in 10 ultracentrifuge-isolated-uEVs samples (4 BPH, 6 Pca)

2016-01-13 | E-GEOD-75441 | biostudies-arrayexpress

Transcription profiling of E. coli strains CFT073, Nissle 1917 and 83972 grown exponentially in MOPS, exponentially in human urine and in biofilms in human urine

Project description:Global transcription profiling of E. coli strains CFT073, Nissle 1917 and 83972 grown exponentially in MOPS, exponentially in human urine and in biofilms in human urine.

2010-09-01 | E-MEXP-2609 | biostudies-arrayexpress

Differentially Expressed Glycoproteins in Pre- and Post-Digital Rectal Examination Urine Samples for Detecting Aggressive Prostate Cancer

Project description:Nonaggressive prostate cancer (NAG-PCa) with Gleason score of 6 is considered as a low-risk disease and does not require clinical interventions. However, current assessment of aggressiveness of PCa is invasive using needle biopsies. Urine is an appealing biospecimen for noninvasive detection of aggressive PCa. Using urine, particularly from easily obtainable from pre-DRE urine specimens, to identify AG-PCa-associated molecular markers is critical for clinical risk stratification. Herein, we acquired quantitative mass spectrometry data for glycoproteins from pre-DRE and post-DRE urine specimens from patients underwent PCa diagnosis with biopsies. Compared with urinary glycoproteins identified from post-DRE urine samples, we confirmed that three previously reported AG-PCa-associated glycoproteins identified in post-DRE urine specimens were also found to be significantly associated with AG disease in pre-DRE urine samples. In addition, new AG-PCa-associated glycoproteins were identified in pre-DRE urine specimens. Our study provides a foundation for further studies of AG-PCa biomarkers using pre-DRE urine specimens.

2023-07-20 | PXD036468 | Pride

Transcription profiling of E. coli CAUTI strains during biofilm growth in human urine

Project description:Gene expression profiling of two different E. coli CAUTI strains during biofilm growth in human urine.<br>

2010-06-09 | E-MEXP-2298 | biostudies-arrayexpress

Transcription profiling of two E. coli ABU strains during biofilm growth in human urine

Project description:Gene expression profiling of two different E. coli ABU strains during biofilm growth in human urine.

2007-02-02 | E-MEXP-926 | biostudies-arrayexpress

microRNA expression profiling of urine and cancer tissues of patients with bladder cancer, and those from the controls with haematuria

Project description:Mid-stream urine was collected from bladder cancer patients prior to surgery. Both tumor tissue and normal bladder mucosa that are located at >3cm away from the tumor edge were obtained by cystoscopy. For the normal controls with haematuria, urine samples were collected from patients who had normal cystoscopic finding and absence of malignancy with >6 months follow-up. All urine samples were centrifuged at 2500 r.c.f. for 20 minutes and the urine supernatant was collected. Total RNA of urine supernatant and frozen tissue was extracted using MirVanaTM PARISTM Kit (Ambion) in accordance with the manufacturerâs recommended protocols. AgilentTM Human miRNA Microarray Chip (Release 13.0, Agilent Technologies, Santa Clara, CA, USA) was used to determine the microRNA expression profiles of the samples.

2014-04-16 | E-MTAB-2573 | biostudies-arrayexpress

Transcription profiling of asymptomatic E. coli strain 83972 grown on urine-agar plates or MOPS-glucose media

Project description:Strain 83972 grown on urine-agar plates compared with MOPS, triplicates.

2011-02-01 | E-MEXP-1453 | biostudies-arrayexpress